Tysabri

New MS Trial Will be First to Compare Stem Cell Therapy with Best Available Biologics
New MS Trial Will be First to Compare Stem Cell Therapy with Best Available Biologics
Xtalks
stem cells
MS
multiple sclerosis
NIH
AHSCT
Biogen
Tysabri
Sanofi
Lemtrada
Roche
Ocrevus
Rituxan
Flag link:
Novartis strikes marketing deal for Polpharma’s potential Tysabri biosimilar
Novartis strikes marketing deal for Polpharma’s potential Tysabri biosimilar
Pharmaforum
Novartis
Sandoz
generics
biosimilars
Tysabri
Polpharma
Flag link:
Biogen scuttles a Tysabri program after the drug fails stroke test, thinning the pipeline
Biogen scuttles a Tysabri program after the drug fails stroke test, thinning the pipeline
Endpoints
Biogen
Tysabri
ischemic stroke
Flag link:
How Biogen Inc. Makes Most of Its Money
How Biogen Inc. Makes Most of Its Money
Motley Fool
Biogen
Tecfidera
Tysabri
MS
multiple sclerosis
Flag link:
Why Roche's New Drug Is Bad News For Biogen
Why Roche's New Drug Is Bad News For Biogen
Barron's
Roche
Biogen
Ocrevus
multiple sclerosis
MS
Tysabri
Tecfidera
Flag link:
Biogen Inc MS Drugs: Deadly Cash Cows?
Biogen Inc MS Drugs: Deadly Cash Cows?
Bidness, ETC
Biogen
MS
multiple sclerosis
Tecfidera
Avonex
Tysabri
Plegridy
Flag link:
Perrigo Can Reach $200 If It Keeps Tysabri Royalties, Lot More If It Sells Them
Perrigo Can Reach $200 If It Keeps Tysabri Royalties, Lot More If It Sells Them
Seeking Alpha
Perrigo
Tysabri
Flag link:
Biogen shares could rise 20% on robust drug pipeline, Barron's contends
Biogen shares could rise 20% on robust drug pipeline, Barron's contends
The Fly on the Wall
Biogen Idec
Tysabri
Avonex
Tecfidera
Eloctate
Alprolix
Flag link:
Catalyst For Perrigo: Sale Of Tysabri Royalties
Catalyst For Perrigo: Sale Of Tysabri Royalties
Seeking Alpha
Perrigo
Tysabri
Biogen Idec
Flag link:
Elan sees sales of prized Tysabri drug rise sharply
Elan sees sales of prized Tysabri drug rise sharply
Reuters
Elan
Royalty Pharma
M&A
Tysabri
Flag link:
Elan completes sale of Tysabri stake to Biogen
Elan completes sale of Tysabri stake to Biogen
Reuters
Tysabri
Elan
Biogen Idec
MS
multiple sclerosis
Flag link:
Elan offers Tysabri dividend, dismisses Royalty offer
Elan offers Tysabri dividend, dismisses Royalty offer
Reuters
Elan
dividends
Tysabri
Royalty Pharma
Flag link:
Elan to return $1 billion to shareholders from multiple sclerosis drug sale
Elan to return $1 billion to shareholders from multiple sclerosis drug sale
Reuters
Elan
Tysabri
share repurchase
Flag link:
A Strong Growth Opportunity In Multiple Sclerosis
A Strong Growth Opportunity In Multiple Sclerosis
Motley Fool
multiple sclerosis
MS
Elan
Biogen Idec
Tysabri
Teva
XenoPort
Sanofi
BG-12
Flag link:
Elan seeks acquisitions after $3.25 bn Biogen Idec deal, rival Bayer eyed on MS treatments
Elan seeks acquisitions after $3.25 bn Biogen Idec deal, rival Bayer eyed on MS treatments
Financial Express
Elan
Bayer
M&A
Biogen Idec
Tysabri
Flag link:
A Win-Win Multiple Sclerosis Deal?
A Win-Win Multiple Sclerosis Deal?
Motley Fool
MS
multiple sclerosis
Tysabri
Biogen Idec
Elan
Flag link:
Biogen pays Elan $3.25 billion to take over MS drug
Biogen pays Elan $3.25 billion to take over MS drug
Reuters
Biogen Idec
Elan
Tysabri
M&A
MS
multiple sclerosis
Flag link:
2013 Should Be Interesting for Multiple Sclerosis Drugs
2013 Should Be Interesting for Multiple Sclerosis Drugs
Motley Fool
MS
multiple sclerosis
Teva
Copaxone
Rebif
Pfizer
Merck KGaA
Biogen Idec
Avonex
Bayer
Betaseron
Novartis
Extavia
Sanofi
Tysabri
Aubagio
Elan
Gilenya
BG-12
Flag link:
Is Biogen Too Good To Be True?
Is Biogen Too Good To Be True?
Seeking Alpha
BiogenIdec
Avonex
Tysabri
Fampyra
Fumaderm
Flag link:
PDL BioPharma expects 2 percent revenue growth on better sales of Herceptin, Lucentis, Tysabri
PDL BioPharma expects 2 percent revenue growth on better sales of Herceptin, Lucentis, Tysabri
Yahoo/AP
PDL Biopharma
guidance
Herceptin
Biogen Idec
Lucentis
Tysabri
Flag link:

Pages